Morgan Stanley
IMVT icon

Morgan Stanley’s Immunovant IMVT Stock Holding History

Morgan Stanley’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175M Buy
4,534,833
+657,956
+17% +$20M 0.01% 1125
2026
Q1 		$96.3M Sell
3,876,877
-969,508
-20% -$25.1M 0.01% 1473
2025
Q4 		$123M Buy
4,846,385
+2,887,359
+147% +$64.4M 0.01% 1274
2025
Q3 		$31.6M Sell
1,959,026
-350,035
-15% -$5.67M ﹤0.01% 2439
2025
Q2 		$36.9M Buy
2,309,061
+999,011
+76% +$15.1M ﹤0.01% 2198
2025
Q1 		$22.4M Buy
1,310,050
+299,426
+30% +$6.26M ﹤0.01% 2580
2024
Q4 		$25M Buy
1,010,624
+192,882
+24% +$5.47M ﹤0.01% 2545
2024
Q3 		$23.3M Buy
817,742
+704
+0.1% +$20.8K ﹤0.01% 2651
2024
Q2 		$21.6M Sell
817,038
-120,923
-13% -$3.44M ﹤0.01% 2578
2024
Q1 		$30.3M Buy
937,961
+406,458
+76% +$14.8M ﹤0.01% 2233
2023
Q4 		$22.4M Buy
531,503
+192,620
+57% +$7.09M ﹤0.01% 2575
2023
Q3 		$13M Sell
338,883
-198,173
-37% -$4.48M ﹤0.01% 2873
2023
Q2 		$10.2M Buy
537,056
+309,965
+136% +$5.78M ﹤0.01% 3142
2023
Q1 		$3.52M Buy
227,091
+56,841
+33% +$986K ﹤0.01% 4066
2022
Q4 		$3.02M Buy
170,250
+77,819
+84% +$980K ﹤0.01% 4162
2022
Q3 		$516K Sell
92,431
-67,240
-42% -$329K ﹤0.01% 5254
2022
Q2 		$622K Sell
159,671
-68,351
-30% -$295K ﹤0.01% 5309
2022
Q1 		$1.26M Sell
228,022
-268,888
-54% -$1.67M ﹤0.01% 4844
2021
Q4 		$4.23M Sell
496,910
-368,336
-43% -$3.04M ﹤0.01% 3886
2021
Q3 		$7.52M Sell
865,246
-677,126
-44% -$6.11M ﹤0.01% 3260
2021
Q2 		$16.3M Buy
1,542,372
+789,721
+105% +$11M ﹤0.01% 2396
2021
Q1 		$12.1M Buy
752,651
+675,882
+880% +$17.8M ﹤0.01% 2457
2020
Q4 		$3.55M Buy
76,769
+71,395
+1,329% +$3.3M ﹤0.01% 3635
2020
Q3 		$190K Sell
5,374
-1,569
-23% -$47.2K ﹤0.01% 5145
2020
Q2 		$169K Sell
6,943
-13,233
-66% -$284K ﹤0.01% 5155
2020
Q1 		$314K Buy
20,176
+19,176
+1,918% +$288K ﹤0.01% 4638
2019
Q4 		$16K Buy
+1,000
New +$11.2K ﹤0.01% 6152

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley's IMVT Position: Q2 2026 in Review

Morgan Stanley increased its Immunovant (IMVT) stake by 17% in Q2 2026, buying an estimated $20M and bringing the position to 4,534,833 shares worth $175M. The position accounts for 0.01% of the portfolio, ranked #1125.

Morgan Stanley first reported a position in IMVT in Q4 2019 and has held it in 27 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Morgan Stanley held 4,534,833 shares of Immunovant worth $175M as of Q2 2026.
  • Morgan Stanley bought 657,956 Immunovant shares in Q2 2026, an estimated $20M.
  • Immunovant made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1125 holding.
  • Morgan Stanley first reported a position in Immunovant in Q4 2019 and has held it in 27 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.